How does Ipamorelin's half-life affect dosing?

Ipamorelin has a plasma half-life of ~2 hr, which is moderate, supporting once-daily dosing in most protocols. The receptor occupancy curve under 1-3x daily subq dosing at 200-300 mcg per dose explains the typical onset timeline for male hormonal and performance endpoints.

What is the regulatory status of Ipamorelin?

Ipamorelin regulatory status: Unapproved in the United States; WADA status banned (s2); research level phase ii in gh deficiency; off-label use widespread. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For male hormonal and performance use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

What should I look for in Ipamorelin sourcing and quality?

Acceptable Ipamorelin certificates of analysis specify: lot-specific (not template) issuance, HPLC purity ≥98%, mass spec confirmation matching 712 Da, endotoxin testing for injectable routes, and third-party accredited laboratory issuance. Template COAs, missing endotoxin data, or vendor-internal labs are red flags. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

Should I cycle Ipamorelin?

Standard cycle for Ipamorelin is 8–12 weeks of 1-3x daily subq 200-300 mcg dosing via subq, followed by a 4 week complete off-period. The off-period is calibrated to Ipamorelin's ~2 hr half-life and to typical receptor downregulation timelines. Continuous indefinite dosing does not show additional clinical benefit in the published literature and increases cumulative downregulation risk.

What is the evidence base for Ipamorelin?

Ipamorelin's evidence base sits at phase ii in gh deficiency; off-label use widespread. The references on this page summarise 2 primary publications supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The male physiology interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

What class of compound is Ipamorelin?

Ipamorelin is classified as a Selective GHRP / ghrelin mimetic. Within this class, alternative names and analogues include NNC 26-0161. The class-level pharmacology shapes both the clinical applications and the safety profile; the male physiology literature treats Ipamorelin alongside its class peers when evaluating relative merits.

Home/ Compounds/ Ipamorelin

Ipamorelin

Men's Health

Male-physiology practitioners evaluate Ipamorelin against the HPG axis, androgenic markers, and downstream effects on body composition, libido, and recovery. Highly selective GHSR1a agonist Triggers pulsatile GH release from somatotrophs without engaging the cortisol or prolactin axis at therapeutic doses. Synergistic with GHRH analogues (CJC-1295) because the two pathways converge on the same pituitary cell.. For men running Ipamorelin alongside TRT, post-cycle restarts, or fertility-aware protocols, baseline labs (total/free testosterone, LH, FSH, estradiol, prolactin, SHBG) and a 6-8 week follow-up panel are the standard monitoring framework at the 200-300 mcg 1-3x daily subq dose.

Male Physiology Applications

Erectile FunctionAndropauseRecoveryMuscle MassTestosterone Optimisation

Key Takeaways

Male-physiology lens: Ipamorelin is evaluated against HPG-axis interaction, TRT compatibility, and prostate / cardiovascular considerations.
Mechanism: Highly selective GHSR1a agonist.
Male monitoring: baseline testosterone (total/free), LH, FSH, estradiol, prolactin, SHBG; 6-8 week follow-up panel.
Male dose: 200-300 mcg 1-3x daily subq via subq; cycle 8-12 weeks.
Male-physiology stack partners: Kisspeptin, Gonadorelin (GnRH), PT-141.

Male Physiology Mechanism

Highly selective GHSR1a agonist. Triggers pulsatile GH release from somatotrophs without engaging the cortisol or prolactin axis at therapeutic doses. Synergistic with GHRH analogues (CJC-1295) because the two pathways converge on the same pituitary cell. For men, the downstream consequences of this mechanism are evaluated against four operational domains: HPG-axis interaction, recovery and body composition, sexual function and prostate, and integration with concurrent TRT or HCG protocols. Ipamorelin's relationship to each is examined below.

Compatibility with TRT and post-cycle protocols

For men currently on TRT or planning a post-cycle restart, Ipamorelin is typically compatible because it operates on a separate (somatotrophic) axis. The dominant interaction to watch for is on the metabolic and recovery layers rather than the hormonal layer. Where the molecule's pharmacology overlaps with HCG, gonadorelin, or kisspeptin, dose layering is the standard approach.

Sexual function and prostate considerations

Where Ipamorelin alters circulating LH, testosterone, or local androgen signalling, prostate considerations become relevant for men over 40. Baseline PSA, periodic re-check, and avoidance of stacking that compounds androgenic load are all reasonable precautions. For molecules whose effects are predominantly outside the HPG axis, the prostate consideration is largely background.

Male body composition and performance response

Male users typically respond to Ipamorelin on the recovery, lean-mass, or visceral-fat dimension depending on the compound's primary pharmacology. Highly selective GHSR1a agonist. Triggers pulsatile GH release from somatotrophs without engaging the cortisol or prolactin axis at therapeutic doses. Synergistic with GHRH analogues (CJC-1295) because the two pathways converge on the same pituitary cell. For men whose body composition goals are driven by training, the dose-timing relative to workouts and sleep is often the critical lever rather than the absolute dose itself.

Male Physiology Applications

TRT Compatibility

Where male users target trt compatibility, Ipamorelin is typically integrated with the broader hormonal protocol — TRT, kisspeptin, gonadorelin, or HCG — rather than used in isolation. The integration approach varies by clinic.

Erectile Function

Erectile Function in men responds to Ipamorelin with effect sizes that vary substantially by baseline status — men with documented suboptimal status respond more strongly than those at the upper end of normal. The protocol pattern in clinical use reflects this.

HPG Axis Support

For hpg axis support in male users, Ipamorelin is most-effective when paired with comprehensive labs (testosterone total/free, LH, FSH, estradiol sensitive, prolactin, SHBG) at baseline and follow-up. Cycle length 8–12 weeks with re-evaluation.

Fat Loss (Male)

Where male users target fat loss (male), Ipamorelin is typically integrated with the broader hormonal protocol — TRT, kisspeptin, gonadorelin, or HCG — rather than used in isolation. The integration approach varies by clinic.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	200-300 mcg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	120-300 mcg	4–6 weeks initial cycle
Men's Health focus	SubQ	200-300 mcg	1-3x daily SubQ
Maintenance phase	SubQ	140-300 mcg	Ongoing with periodic pauses

Dose timing for Ipamorelin is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses. Fasted dosing produces stronger GH pulses; meal-paired dosing blunts the response.

Stacking

Ipamorelin stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from men's-health clinicians.

Ipamorelin + Kisspeptin: Activates the KISS1R (GPR54) on GnRH neurons in the hypothalamus, triggering GnRH release. Pairs naturally with Ipamorelin's mechanism in male physiology protocols.
Ipamorelin + Gonadorelin (GnRH): Binds the GnRH receptor on anterior pituitary gonadotrophs in a pulsatile fashion to stimulate LH (and to a lesser extent FSH) release. Pairs naturally with Ipamorelin's mechanism in male physiology protocols.
Ipamorelin + PT-141: Activates MC4R in the hypothalamus and other CNS regions involved in sexual response. Pairs naturally with Ipamorelin's mechanism in male physiology protocols.
Ipamorelin + CJC-1295 without DAC (Mod GRF 1-29): Same GHRH-receptor agonism as DAC variant. Pairs naturally with Ipamorelin's mechanism in male physiology protocols.

Safety & Regulatory Status

WADA: Banned (S2) FDA: Unapproved Research: Phase II in GH deficiency; off-label use widespread

Cleanest side-effect profile among GHRPs. Mild flushing possible. Site reactions occasional.

Lens-specific safety considerations for male physiology use of Ipamorelin: Cleanest side-effect profile among GHRPs. Mild flushing possible. Site reactions occasional. Additional male physiology monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Ipamorelin selective growth hormone secretagogue

PMID 9849822

Supporting

Ipamorelin clinical pharmacology

PMID 10882754

Ipamorelin vs Related Peptides

Compound	Profile	Onset	Best For
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	Men's Health
Kisspeptin	Hypothalamic upstream regulator of GnRH	~28 min IV	The upstream master regulator of GnRH neurons — driving the entire HPG axis from above
Gonadorelin (GnRH)	Hypothalamic decapeptide	~2-4 min	The natural decapeptide that drives pituitary release of LH and FSH — used clinically and increasingly as an HCG alternative during testosterone therapy
PT-141	Melanocortin receptor agonist	~2-3 hr	An MC3R/MC4R agonist derived from Melanotan II — FDA-approved as bremelanotide for HSDD in premenopausal women

Frequently Asked Questions

Best time of day to dose for male users?

The pragmatic schedule is morning fasted for compounds engaging the GH axis (preserving the natural overnight pulse), evening for compounds supporting sleep, and PRN for compounds with acute effects (PT-141, etc.). The schedule should fit the user's daily reality more than the textbook ideal.

What blood work should I run on this protocol?

Standard male protocol baseline: total and free testosterone, LH, FSH, estradiol (sensitive), prolactin, SHBG, fasting glucose, HbA1c, hsCRP, lipid panel, CBC, CMP. Follow-up at week 6–8 with the same panel. Add IGF-1 for any GH-axis compound. Add PSA for men over 40.

Can I use Ipamorelin during a cut?

Yes, and several compounds in this class are specifically protective of lean mass in caloric deficit. The dose-timing relative to training and the protein intake matter more than the absolute dose. Cardiovascular and metabolic monitoring continues to apply.

Does Ipamorelin affect hair, prostate, or erythrocyte production?

Where Ipamorelin elevates downstream testosterone or DHT signalling, hair loss in genetically susceptible men is a theoretical consideration; prostate effects and erythrocyte expansion are dose-dependent concerns particularly for men over 40. Routine monitoring (PSA, hematocrit) is appropriate for any protocol producing meaningful androgenic shifts.

Will Ipamorelin affect testosterone or my HPG axis?

Ipamorelin's effect on the HPG axis depends on its primary mechanism. Direct HPG-axis engagement is not the principal mechanism, but indirect effects via inflammation, metabolic status, or hepatic SHBG may produce hormone shifts that warrant baseline and follow-up labs. The standard male monitoring panel applies.

What is the standard dosing protocol for Ipamorelin?

Conventional Ipamorelin dosing is 200-300 mcg 1-3x daily subq via subq. For male hormonal and performance use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

Clinical Protocol

Start a Ipamorelin Protocol

Alukard provides physician-supervised men's health protocols with GMP-certified Ipamorelin and GMP-certified compounds with comprehensive hormone panels.

Get Protocol

Quick Facts

Molecular weight: 712 Da
Sequence length: 5 aa
Half-life: ~2 hr
WADA: Banned (S2)
FDA: Unapproved
Research: Phase II in GH deficiency; off-label use widespread

Stack Partners

Kisspeptin

Gonadorelin (GnRH)

PT-141

CJC-1295 without DAC (Mod GRF 1-29)

Research Note

All male physiology applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Ipamorelin unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised men's health protocols

Start Your Male Physiology Protocol for Ipamorelin

Alukard provides physician-supervised men's health protocols with GMP-certified compounds with comprehensive hormone panels.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised